Pharmaceutical Executive November 9, 2023
Fruquintinib (Fruzaqla) is the first novel chemotherapy-free treatment option approved for metastatic colorectal cancer in more than a decade.
The FDA has approved fruquintinib (Fruzaqla) to treat adults with metastatic colorectal cancer who received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and an anti-EGFR therapy for cases that are RAS wild-type and medically appropriate.1
Fruzaqla is an oral, highly selective, small molecule VEGF receptor inhibitor. Because of the kinase selectivity of Fruzaqla, the risk of off-target toxicity is less than the risk with multikinase inhibitors, including regorafenib.2
“There is a pressing need for new treatments for individuals with metastatic colorectal cancer, who have had limited options and continue to face poor outcomes. Fruzaqla is the first...
Today's Sponsors
Today's Sponsor